Immunization of rhesus monkeys with split and subunit vaccines of SIVagmTYO-7.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Immunization of rhesus monkeys with split and subunit vaccines of SIVagmTYO-7.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 121. Unique Identifier : AIDSLINE PRIM10/93200964
Luke W; Stahl-Hennig C; Wyand MS; Manson K; Petry H; Voss G; Hunsmann G; German Primate Center, Gottingen.

Abstract: Three rhesus monkeys were immunized with gp130 micelles linked to KLH three times four weeks apart with a total of 60 micrograms of gp130 in incomplete Freund's adjuvant. Three additional rhesus monkeys were vaccinated with a Tween-Ether (TE) extract of purified SIVagmTYO-7 following the same immunization schedule as above. Two control animals received KLH. After a rest period of three years, all animals were immunized again two times four weeks apart and challenged two weeks later with 10 MID50 of SIVmac251/32H. At the time of challenge, all immunized animals had developed antibody titers between 10(4) to 10(5) against the SIVmac251 gp130. Antibody titers against cellular components were between 5 x 10(1) and 2.4 x 10(3). Neutralizing antibodies could not be detected. Two weeks after challenge, the gp130-immunized and the control animals showed a strong SIVmac251/32H antigenemia in the plasma, whereas animals received TE extracts were negative. All gp130-immunized animals, two TE extract-immunized animals and the two control animals were also positive in virus reisolation from plasma. However, one ogf the TE extract-immunized animals showing the highest anti SIVmac gp130 titer was negative in virus reisolation from plasma two weeks after challenge. Further results about sequential virus reisolation, determination of virus load by PCR and the influence of the immunization with gp130 and TE extracts on the development and progression of the disease will be discussed.

Keywords: Animal *Antibody Formation Freund's Adjuvant *Immunization Macaca mulatta Micelles Neutralization Tests Polymerase Chain Reaction/METHODS *SIV/ISOLATION & PURIF Vaccines, Synthetic/*PHARMACOLOGY Viral Envelope Proteins/*IMMUNOLOGY Viral Vaccines/*PHARMACOLOGY ABSTRACT
930630
M9361056

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .